Latest news with #Indapamide
Business Standard
a day ago
- Health
- Business Standard
TOPSPIN Study by the Centre for Chronic Disease Control (CCDC) Finds Two-drug Combination Therapies Effective in Improving Blood Pressure Control in Indians
NewsVoir New Delhi [India], July 30: A new study, entitled TOPSPIN, coordinated by the Centre for Chronic Disease Control (CCDC) New Delhi, in collaboration with the All India Institute of Medical Sciences (AIIMS) New Delhi, and Imperial College London, examined 1,981 patients with uncontrolled hypertension across 32 hospitals in India. The findings showed that three two-drug combination therapies - Amlodipine plus Perindopril, Amlodipine plus Indapamide, and Perindopril plus Indapamide - were equally effective and safe in lowering both ambulatory and office blood pressure. TOPSPIN is the first-ever randomised study to test the choice of first-line two-drug combination therapy in a single pill among South Asians. The study findings are published in Nature Medicine, one of the top medicine journals. South-Asians represent one-fourth of the world population, and India alone constitutes one-sixth of the global population. Hypertension is a public health crisis affecting over one billion adults worldwide, including over 300 million living in India. Innovative solutions are needed to curb the growing tide of high blood pressure, which is the single highest risk factor for global deaths, and which requires effective management solutions. Current guidelines widely recommend initiating treatment with two-drug combinations, preferably in a single-pill formulation, to enhance blood pressure control. However, the suitability of these combinations for the South-Asian population remains unknown, as there are no studies in this regard. The key takeaways are that all three combinations were equally effective in reducing blood pressure and were safe for patients. What did the TOPSPIN study find? - Blood pressure dropped significantly after 6 months, by around 14/8 mmHg when measured over 24 hours and about 30/14 mmHg in clinic settings. - Nearly 70% of patients reached the recommended blood pressure target below 140/90 mmHg, five times higher than India's current average control rate. - The pills were well-tolerated, with less than 3% of patients reporting side effects serious enough to stop treatment. What do the Study leaders say? "This study shows that a single daily pill with two drugs can be a simple and powerful way to manage blood pressure in Indian and South Asian patients," said Prof. Dorairaj Prabhakaran, Executive Director of CCDC and one of the study's lead authors. "These findings can help guide doctors and policymakers. If added to India's list of essential medicines and made available at primary health centres, these pills could greatly improve blood pressure control in the country." Prof. Ambuj Roy, Professor of Cardiology at AIIMS Delhi, added, "Nearly 70% of patients got their blood pressure under control, a huge improvement over the current national average. And the pills were safe and easy to use. This study gives clear guidance for better hypertension care." Prof. Neil Poulter, Professor at Imperial College London, emphasized the importance of studying how medicines work in different populations. "Just as earlier research in Africa showed different results, this study gives strong evidence on what works best in South Asians." The TOPSPIN study results could help improve treatment not only in India, but also for South Asians living around the world.
Fashion Value Chain
a day ago
- Health
- Fashion Value Chain
TOPSPIN Study by the Centre for Chronic Disease Control (CCDC) Finds Two-drug Combination Therapies Effective in Improving Blood Pressure Control in Indians
A new study, entitled TOPSPIN, coordinated by the Centre for Chronic Disease Control (CCDC) New Delhi, in collaboration with the All India Institute of Medical Sciences (AIIMS) New Delhi, and Imperial College London, examined 1,981 patients with uncontrolled hypertension across 32 hospitals in India. The findings showed that three two-drug combination therapies – Amlodipine plus Perindopril, Amlodipine plus Indapamide, and Perindopril plus Indapamide – were equally effective and safe in lowering both ambulatory and office blood pressure. TOPSPIN is the first-ever randomised study to test the choice of first-line two-drug combination therapy in a single pill among South Asians. The study findings are published in Nature Medicine, one of the top medicine journals. A doctor checking the blood pressure of a patient South-Asians represent one-fourth of the world population, and India alone constitutes one-sixth of the global population. Hypertension is a public health crisis affecting over one billion adults worldwide, including over 300 million living in India. Innovative solutions are needed to curb the growing tide of high blood pressure, which is the single highest risk factor for global deaths, and which requires effective management solutions. Current guidelines widely recommend initiating treatment with two-drug combinations, preferably in a single-pill formulation, to enhance blood pressure control. However, the suitability of these combinations for the South-Asian population remains unknown, as there are no studies in this regard. The key takeaways are that all three combinations were equally effective in reducing blood pressure and were safe for patients. What did the TOPSPIN study find Blood pressure dropped significantly after 6 months, by around 14/8 mmHg when measured over 24 hours and about 30/14 mmHg in clinic settings. Nearly 70% of patients reached the recommended blood pressure target below 140/90 mmHg , five times higher than India's current average control rate. The pills were well-tolerated, with less than 3% of patients reporting side effects serious enough to stop treatment. â What do the Study leaders say 'This study shows that a single daily pill with two drugs can be a simple and powerful way to manage blood pressure in Indian and South Asian patients,' said Prof. Dorairaj Prabhakaran, Executive Director of CCDC and one of the study's lead authors. 'These findings can help guide doctors and policymakers. If added to India's list of essential medicines and made available at primary health centres, these pills could greatly improve blood pressure control in the country.' Prof. Ambuj Roy, Professor of Cardiology at AIIMS Delhi, added, 'Nearly 70% of patients got their blood pressure under control, a huge improvement over the current national average. And the pills were safe and easy to use. This study gives clear guidance for better hypertension care.' Prof. Neil Poulter, Professor at Imperial College London, emphasized the importance of studying how medicines work in different populations. 'Just as earlier research in Africa showed different results, this study gives strong evidence on what works best in South Asians.' â The TOPSPIN study results could help improve treatment not only in India, but also for South Asians living around the world.
The Hindu
5 days ago
- Health
- The Hindu
Study recommends two half-dose combination of drugs in a single pill for good blood pressure control in Indians
With evidence lacking thus far for guiding optimal combination hypertension therapy in South Asian patients, a recent study has recommended half doses of two drugs in a single pill combination right from the start of treatment for hypertension. The paper, 'Comparison of dual therapies for hypertension treatment in India', published in the journal Nature Medicine, investigated the blood pressure (BP)-lowering efficacy and safety of three commonly-recommended antihypertensive combinations in a single pill in a multi-centre trial across 32 sites in India. Nearly 2,000 adults with uncontrolled or untreated hypertension were studied, and interventions included three single-pill dual combinations: Amlodipine + Perindopril, Perindopril + Indapamide and Amlodipine + Indapamide. All three combinations, in patients aged 30–79, delivered equivalent BP reductions and similar rates of BP control, researchers said. All combinations were equally safe and effective with high tolerability over six months, they wrote in the paper. 'It must be noted that we are not recommending a multi-drug regimen. Polypharmacy will only lead to discontinuation of treatment,' says Prabhakaran Dorairaj, principal investigator of the study, from the Centre for Chronic Disease Control, New Delhi. 'What we are recommending is to start with half doses of two drugs in a single pill combination. If BP control does not happen, then it is important to titrate to full doses. Despite this, if BP continues to be higher than 140/90, then additional drugs are to be added,' he explains. 'It is really astounding that we have been basing treatment on Western guidelines, so far,' Dr. Prabhakaran adds. This study tests the global guidelines for hypertension treatment among patients in India, since these combinations are already available here. These drugs work through multiple pathways and are synergistic, with low side effects, he says. 'Many physicians, even cardiologists, think that they should start with a low dose and then keep escalating it,' says Nagendra Boopathy, co-author and interventional cardiologist, Sri Ramachandra Medical Centre, Chennai. 'Even patients are reluctant to start on drugs, but these combinations we have tested are really effective in bringing down BP, and the side effects are minor,' he adds. The side effects observed during the trial included cough, swelling of feet and lower potassium in some subgroups, and not statistically significant. Dr. Prabhakaran adds, 'The biggest problem in India is poor control of hypertension. Only around 20% of individuals with hypertension are treated to target in urban areas, and it is even lower in rural areas. It is estimated that a 10 mm reduction in BP among people with hypertension can prevent 40% of strokes. A vibrant pharmaceutical industry, which makes these single combinations and pooled procurement via the public health system, should help drive down prices, making this a key strategy in the battle against hypertension.'
